|
Canada-0-EXPLOSIVES Company Direktoryo
|
Company News :
- ICD Therapy for Primary Prevention in HFrEF: Key Points
Etiology of cardiomyopathy impacts the risk for SCD as arrhythmogenic cardiomyopathies such as arrhythmogenic right ventricular dysplasia and LMNA-associated disease, and channelopathies In such populations, ICD indications differ by genetic etiology, and family and clinical history
- Evolution of primary prevention implantable cardioverter-defibrillator . . .
This study aimed to evaluate temporal trends in appropriate ICD interventions and ICD-resistant mortality (ICDRM) in patients with ischemic (ICM) and nonischemic cardiomyopathy (NICM) and a primary prevention (PP) ICD indication
- Cardiac Implantable Electronic Devices in Ischemic Cardiomyopathy
This review discusses the range of device therapy for ischemic cardiomyopathy (ICM) This article will review the primary data supporting guideline indications for cardiac implantable electronic devices in patients with ICM, with a focus on primary secondary prevention transvenous implantable cardioverter defibrillators (ICDs), cardiac
- Characterization of ischemic etiology in heart failure with reduced . . .
A total of 145 HFrEF RCTs were selected, of which 133 (91 7 %) enrolling both ischemic and non-ischemic patients (629 patients study on average, median age 64 8 years and ejection fraction 28 2 %) The majority of these RCTs (84 2 %) lacked of clear ischemic etiology definition
- Primary Prevention Implantable Cardioverter-Defibrillators in Ischemic . . .
Purpose of review Implantable cardiac defibrillators have been utilised in ischemic cardiomyopathy patients, in a primary prevention capacity since 1996 The early trials utilised electrophysiology studies to identify high-risk individuals, but contemporary imaging modalities were not widely available when these trials were conducted Recent findings This review assess evidence from previous
- Long-Term Outcomes in ICD: All-Causes Mortality and First Appropriate . . .
ICD implanted in secondary prevention is associated with a 28% reduction of mortality, 1 ,2 but the role of ICD in primary prevention of sudden cardiac death (SCD) is not completely set yet; both in patients with ischemic and nonischemic etiology, left ventricular ejection fraction (LVEF) has been identified as the most significant parameter 3–6
- The Optimal Timing of Primary Prevention Implantable Cardioverter . . .
In the present review, we examine the landmark RCTs in primary prevention of SCD in patients with HFrEF, summarise the novel medical therapies that have emerged since the publication of those trials, discuss the optimal timing to ICD referral and implantation, and briefly highlight cardiomyopathy subtypes that necessitate alternative thresholds
- Implantable cardioverter defibrillator use for primary prevention in . . .
The aim of this European Heart Rhythm Association survey was to evaluate the clinical practice regarding implantation of ICD for primary prevention among European countries in patients with non-ischaemic and ischaemic heart disease
- Comparative analysis of implantable cardioverter- defibrillator . . .
the outcomes of ICD implantation in a contemporary cohort of patients with LVEF ≤ 35%, focusing on both ischemic and non-ischemic cardiomyopathy By analyzing clinical outcomes, the utilization
|
|